Recently, owing to improvement in the tools for selection based on favorable tumor biology, incorporation of mammalian target of rapamycin inhibitors (mTORi), and aggressive local treatment after recurrence, there is a belief that tumor recurrence, however, a feared event, does not immediately mean poor survival outcomes [1,3,5]. The gene discussed is MTOR; the disease is neoplasm.